RAPP insider signal: 4 reporting investors
Rapport Therapeutics, Inc. Common Stock (RAPP): 4 distinct insiders, 5 supporting records; latest filing 2026-10-22. Financials and technicals use the dated research snapshot.
These are newly observed filings, not necessarily trades made today. How to read the dates and figures →
Financials & technicals
The disclosure signal
4 different insiders reported purchases in disclosures filed within 30 days. Review the transaction dates and original filings. The covered purchase records total 52,594 reported shares and approximately USD 1,422,796.7 calculated from reported shares and prices. Weighted-average prices and rounding mean this is an estimate. This is a disclosure-research flag, not a forecast or an instruction to buy.
Who reported the activity
MARAGANORE JOHN (director) reported a purchase in RAPP. Reported shares: 8,239; reported transaction value: $217,344. Transaction date: 2026-10-22; filed 2026-10-22. Security: Common Stock. Reported classification: P-Purchase.
Silva Paul M (director) reported a purchase in RAPP. Reported shares: 3,680; reported transaction value: $99,636. Transaction date: 2026-10-22; filed 2026-10-22. Security: Common Stock. Reported classification: P-Purchase.
MARAGANORE JOHN (director) reported a purchase in RAPP. Reported shares: 1,172; reported transaction value: $31,547.08. Transaction date: 2026-10-22; filed 2026-10-22. Security: Common Stock. Reported classification: P-Purchase.
Young Wendy B. (director) reported a purchase in RAPP. Reported shares: 3,789; reported transaction value: $99,991.71. Transaction date: 2026-10-22; filed 2026-10-22. Security: Common Stock. Reported classification: P-Purchase.
PAUL STEVEN M (director) reported a purchase in RAPP. Reported shares: 35,714; reported transaction value: $974,277.92. Transaction date: 2026-10-22; filed 2026-10-22. Security: Common Stock. Reported classification: P-Purchase.
Financials
Company profile classification: Healthcare / Biotechnology.
For Q2 2026, period ended 2026-06-30, reported revenue was USD 0 and net income was USD -56,615,000; diluted EPS was -1.19. Same-period operating cash flow: USD -41,455,000. Cash and cash equivalents: USD 63,612,000; total debt: USD 10,105,000. These are reported period figures, not current cash balances.
Technicals
The completed close on 2026-10-22 was USD 26.53 (Split-adjusted daily close). SMA20: 30.39; SMA50: 39.48; SMA200: 35.74. RSI14: 31.61; ATR14: 2.46; volume versus the prior 20-session average: 1.69 times. Prior 20-session closing support: 25.06; resistance: 33.91. A sustained close above resistance would clear that dated range; a break below support would weaken the setup. These are conditional observations, not price targets.
Earnings context
The saved earnings-history release date is 2026-08-05, with provider-reported EPS of -1.19. The consensus accounting basis has not been independently matched, so no EPS beat or miss claim is made. The provider calendar currently lists 2026-11-05; the issuer announcement and release time are unconfirmed. This is a calendar estimate to verify, not a guaranteed release date.
Risks and coverage
Reported purchases do not prove investment intent or predict returns. Review operating losses, financing needs, corporate events, liquidity and the original filing footnotes alongside the charts. Fund comparisons use quarter-end share holdings, not known trade execution dates. Congressional amounts are ranges. Coverage is limited to the saved feeds; other disclosures may exist. Missing supplementary figures remain unspecified.
Read the original filings
Educational disclosure research. Purchases and holding changes are evidence for further research, not recommendations or predictions. Editorial standards · Sources and coverage